Edwards lifesciences reports second quarter results

Irvine, calif.--(business wire)--edwards lifesciences (nyse: ew) today reported financial results for the quarter ended june 30, 2024. highlights and outlook q2 sales grew 7%; constant currency1 sales grew 8% q2 tavr sales grew 5%; constant currency1 sales grew 6% q2 tmtt sales grew 75%; increasing contribution to edwards' growth q2 eps of $0.61; adjusted1 eps of $0.70 significant tavr and tmtt clinical evidence to be presented at tct in october 2024 positive evoque introduction with excellent.
EW Ratings Summary
EW Quant Ranking